Intended for healthcare professionals


Update to living systematic review on drug treatments for covid-19

BMJ 2020; 371 doi: (Published 17 December 2020) Cite this as: BMJ 2020;371:m4852

This living systematic review by Siemieniuk and colleagues (BMJ 2020;370:m2980) has been updated. For the latest update, visit doi:10.1136/bmj.m2980. The latest version of this living systematic review includes results for new interventions azithromycin, colchicine, interferon beta, interferon gamma, interferon kappa plus trefoil factor 2, rhG-CSF, tocilizumab (but certainty is low or very low); evidence that remdesivir may not reduce mortality (low certainty) or time to symptom resolution (moderate certainty); evidence that glucocorticoids probably reduce length of ICU stay (low certainty) and increase ventilator-free days (moderate certainty).

View Abstract